MindMed currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the biotech sector are Castle Biosciences, Inc. CSTL, CytomX Therapeutics CTMX and Spero Therapeutics SPRO, each ...

(NASDAQ:MNMD – Free Report) by 9.9% in the third quarter, according to its most recent 13F filing with the Securities and ...

Fintel reports that on December 20, 2024, Chardan Capital initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a Buy ...

Omeros Corporation's (OMER) stock surged 55% after positive trial results for narsoplimab, a potential treatment for stem ...

Detailed price information for Mind Medicine Mindmed Inc (MNMD-Q) from The Globe and Mail including charting and trades.

Oppenheimer analyst Francois Brisebois maintained a Buy rating on Mind Medicine (MNMD – Research Report) today and set a price target of ...

MindMed Inc. has announced the dosing of the first patient in its phase 3 Voyage study of MM120 ODT, a pharmaceutically ...

Mind Medicine (MNMD) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

grew its holdings in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) by 8.3% during the third quarter, ...

Buy MNMD near 5.59 target 7.86 stop loss @ 5.57 Details The technical summary data tells us to buy MNMD near 5.59 with an upside target of 7.86. This data also tells us to set a stop loss @ 5.57 to ...

纽约 - 市值5.4852亿美元的临床阶段生物制药公司Mind Medicine (MindMed) Inc. (NASDAQ: MNMD)今日宣布,其用于治疗广泛性焦虑障碍(GAD)的实验性药物MM120 ODT已获得英国药品和保健品监管局(MHRA)颁发的创新通行证。根据InvestingPro的数据,该公司今年以来的股价表现出色,年初至今 ...